Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 3 of 102, showing 5 Applications out of 509 total, starting on record 11, ending on 15

# Protocol No Study Title Investigator(s) & Site(s)

11.

ECCT/24/12/03   PrEMIA Implementation study
    Multi-product PrEP delivery to young women seeking reproductive health services and coverage of HIV prevention   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
KEMRI-CCR PHRD( (THIKA) PROJECT
 
View

12.

ECCT/25/01/01   FLORAL
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Bernhard Ogutu
Site(s) in Kenya
1. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
2. Gertrude’s Children’s Hospital (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
5. KEMRI WALTER REED KERICHO (Kericho county)
6. KEMRI Kondele Children\'s Hospital (Kisumu county)
7. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
 
View

13.

ECCT/24/12/01   PDMC-Saves Lives (PDMC-SL)
    Delivery strategies for malaria chemoprevention in the post-discharge management of hospitalised children with severe anaemia or severe malaria: cluster and individually randomised controlled implementation trials with nested economic evaluation in Kenya and Benin   
Principal Investigator(s)
1. Juliet Otieno Awori
2. Simon Kariuki
Site(s) in Kenya
Health facilities with blood transfusion services in malaria-endemic areas in Western Kenya
 
View

14.

ECCT/24/12/02   IAVI C113
    IAVI C113: A Phase 2b, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of a candidate tuberculosis (TB) vaccine, MTBVAC, against TB disease in interferon gamma release assay positive adolescents and adults aged 14-45 years, living in a TB endemic region.   
Principal Investigator(s)
1. Videlis Nduba
2. Tina Lucas
Site(s) in Kenya
1. KEMRI,Centre for Respiratory Diseases Research (Nairobi City county)
2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
 
View

15.

ECCT/25/03/01   MK-5684_MSD (mCRPC)
     A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA)    
Principal Investigator(s)
1. PROF MANSOOR NOORALI SALEH
Site(s) in Kenya
AGA KHAN UNIVERSITY HOSPITAL NAIROBI
 
View